Yamo Pharmaceuticals is a clinical-stage company dedicated to developing L1-79, an oral treatment targeting core social-interaction deficits in individuals with Autism Spectrum Disorder (ASD). In 2016, Yamo Pharmaceuticals filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA).

The following year, Yamo completed a randomized, double-blind, placebo-controlled 4-week study (Study HT02-121) in 42 male patients aged 13 to 21 years with autism. Based on encouraging results, including positive trends in the Vineland-II Socialization Standard Score, Yamo was granted Fast Track Designation by the FDA in May 2018.

In June 2024, Yamo completed a Phase 2 clinical trial evaluating L1-79 in adolescents and young adults with ASD. On July 30, 2024, Yamo announced positive results from this study, highlighting significant improvements in socialization metrics (press release).

For more information about Yamo Pharmaceuticals, L1-79, or opportunities to participate in future clinical studies, please contact us directly.